Your browser doesn't support javascript.
loading
mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model.
Sittplangkoon, Chutamath; Alameh, Mohamad-Gabriel; Weissman, Drew; Lin, Paulo J C; Tam, Ying K; Prompetchara, Eakachai; Palaga, Tanapat.
Affiliation
  • Sittplangkoon C; Graduate Program in Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
  • Alameh MG; Center of Excellence in Immunology and Immune-Mediated Diseases, Chulalongkorn University, Bangkok, Thailand.
  • Weissman D; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
  • Lin PJC; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
  • Tam YK; Acuitas Therapeutics, Vancouver, BC, Canada.
  • Prompetchara E; Acuitas Therapeutics, Vancouver, BC, Canada.
  • Palaga T; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center-Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Front Immunol ; 13: 983000, 2022.
Article in En | MEDLINE | ID: mdl-36311701
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma, Experimental / Interferon Type I Type of study: Prognostic_studies Limits: Animals Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: Thailand Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma, Experimental / Interferon Type I Type of study: Prognostic_studies Limits: Animals Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: Thailand Country of publication: Switzerland